Member News

MEMBER NEWS: Beringea invests in record $39.5 million Series C Round for Delphinus Medical Technologies


FARMINGTON HILLS, MICH. (September 10, 2015)— Beringea, a private equity firm providing growth capital to market-leading businesses, is pleased to announce a follow-on investment in Delphinus Medical Technologies, Inc., the leader in advanced breast ultrasound technology.  The company has secured an unprecedented Series C funding round of $39.5 million, the single largest amount ever raised for a healthcare imaging company in the Midwest, as well as the largest for a medical device company in Michigan. 

BiotechnologyBeringea joins current Delphinus investors Arboretum Ventures and North Coast Technology Investors, as well as new investors Venture Investors, Hopen Life Science Ventures and Waycross Ventures, in the syndicate.  The oversubscribed financing round will be used to underwrite regulatory efforts and fuel the commercialization plans for SoftVue™, Delphinus’ breakthrough whole breast ultrasound system that allows physicians to image the entire breast, including the chest wall, for diagnostic imaging purposes.

Michael Gross, managing director at Beringea

Michael Gross, managing director at Beringea

“Delphinus’ innovative approach to ultrasound breast imaging has the potential to result in more accurate cancer screening for millions of women with dense breast tissue, without the high false positive rates generated from other ultrasound screening techniques.” said Michael Gross, managing director at Beringea. “This new round of funding, along with the world-class management team that has been assembled, will allow Delphinus to complete a pivotal multi-center PMA trial and bring this game changing technology to market.”

Currently, 24 states have enacted legislation requiring that women who have dense breast tissue receive notification of it in their mammography report. The legislation covers nearly two-thirds of the women in the United States. Dense breast tissue increases a woman’s chance of having breast cancer, yet presents a greater challenge in detecting it with mammography alone. Supplemental breast imaging, such as breast ultrasound, may benefit women with dense breast tissue.

As an ultrasound technology, SoftVue offers the potential to not only assist physicians in finding more cancers, but also to reduce the false positive rates that have troubled other breast imaging techniques. SoftVue’s unparalleled, sophisticated design incorporates a circular ultrasound transducer, unique to medical imaging, presenting cross-sectional ultrasound slices through the entire volume of breast tissue. The multi-dimensional imaging captures not only reflected echoes in a 360-degree array, but also signals passing through the breast, depicting tissue characterization.

Mark J. Forchette, president and CEO of Delphinus

Mark J. Forchette, president and CEO of Delphinus

“Our Series C financing demonstrates the confidence that sophisticated medical device investors have in our SoftVue automated whole breast ultrasound technology, and its potential to serve women with a transformational approach to breast imaging,” said Mark J. Forchette, president and CEO of Delphinus. “This syndicate of investors combines the robust strength of the Midwest venture capital community with investors in Silicon Valley to provide diverse support for our breakthrough system, which was invented right here in Michigan.”

Delphinus is planning to launch a large multi-site clinical study to support a PMA application for a supplemental screening indication for women with dense breasts. Later this year, the company will begin by prospectively imaging 10,000 women with SoftVue in eight centers around the country. Using the imaging, a reader study will then be conducted. The study will compare SoftVue to digital mammography, and demonstrate its effectiveness in finding cancers that are not seen with mammography, while reducing false positives, thereby reducing the need for follow-up testing. False positives have gained recent attention in other breast imaging technologies and have been implicated in driving up healthcare costs, as well as patient anxiety.


About Delphinus Medical Technologies, Inc.
Headquartered in Plymouth, Mich. with a satellite office in Sunnyvale, Calif., Delphinus Medical Technologies, Inc. is a pioneering medical imaging company that has developed SoftVue™, the first circular array transducer technology that has received sequential U.S. Food and Drug Administration clearances. The patented technology is a whole breast ultrasound imaging device that delivers no radiation, requires no compression, and images the entire breast with a single scan. SoftVue is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography. Delphinus was founded as a spin out of the Karmanos Cancer Institute in Detroit and is capitalized through principal investments by Arboretum Ventures, Ann Arbor, Mich., Beringea, Farmington Hills, Mich., North Coast Technology Investors, Ann Arbor, Mich., Venture Investors, Madison, Wis., Hopen Life Science Ventures, Grand Rapids, Mich., and Waycross Ventures, Menlo Park, Calif. For more information, visit www.delphinusmt.com.

About Beringea
Beringea, LLC provides equity and/or mezzanine debt to small- and-middle market companies. The Firm, which includes Michigan-based Beringea, LLC and its London, UK office Beringea LLP, invests in portfolio companies operating in a range of sectors, including health care, information technology, advanced manufacturing, media and specialized consumer products.

With flexible capital solutions, extensive investing experience and offices in the U.S. and UK, Beringea’s team offers its portfolio companies the resources to grow their businesses and create value for stakeholders. For more information, visit www.beringea.com.

In the United States of America, Beringea operates as an SEC-registered investment advisor, Beringea, LLC. In the United Kingdom, this document is issued by Beringea LLP, a firm authorized and regulated by the Financial Conduct Authority. Beringea LLP is a limited liability partnership registered in England and Wales with company number OC342919, and its registered office is at 39 Earlham Street, London, WC2H 9LT, UK. This document is intended solely to provide information regarding Beringea’s potential financing capabilities for prospective portfolio companies.


Posted September 14, 2015 in Venture Firm News